TP53 and B-cell chronic lymphocytic leukemia: Because the anti-CD52 monoclonal antibody alemtuzumab and high-dose steroids kill CLL cells through a p53 independent mechanism the efficacy of these drugs in combination was assessed 39, producing a 65% CR rate, with 36% MRD-disease and PFS median of 18.3 months in untreated patients.